IRA W. WEISS, M.D.; LILLIAN FISHER, B.A.; JAMES M. PHANG, M.D.
A young man with severe debility from myositis ossificans progressiva was treated with sodium etidronate, a diphosphonate known to reduce the rates of hydroxyapatite formation and dissolution. He showed progressive improvement while receiving therapy. Radiocalcium kinetics and metabolic balance studies documented the reduction of bone mineral accretion and resorption rates. A lack of change in body calcium balance during diphosphonate administration suggests that sodium etidronate can initiate the desired clinical effect without demineralizing skeletal bone.
WEISS IW, FISHER L, PHANG JM. Diphosphonate Therapy in a Patient with Myositis Ossificans Progressiva. Ann Intern Med. ;74:933–936. doi: 10.7326/0003-4819-74-6-933
Download citation file:
Published: Ann Intern Med. 1971;74(6):933-936.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use